The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.
4 reports, 2 independent
Updated Jul 13
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 3
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- FDA approved subcutaneous dose for lecanemab initiation.Sub-event
- Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo.Sub-event
FDA approved BLA for LEQEMBI IQLIK; Biogen HQ in Cambridge, Eisai HQ in Tokyo.1 source
Keep exploring
The entities involved
-
Cambridge
city in Middlesex County, Massachusetts, United States of America
-
Biogen
American multinational biotechnology company
Nothing else this week.
- FDA
-
Eisai
Japanese pharmaceutical company
Nothing else this week.
Related events
- Cronus Pharma LLC, headquartered in East Brunswick, is launching products in the U.S. market and seeking FDA approval.
- Biogen, Eisai, and Morgan Stanley announced strategic shifts regarding the LEQEMBI treatment pathway simplification.
- Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
Coverage
Newest first; wire copies grouped- PR NewswireFDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease LEQEMBI IQLIK is the first and only anti-amyloid treatment t
- ZacksHow Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings? AbbVie ABBV holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox Therapeutic